Adcom lights way to approval of first U.S. gene therapy in rare disease

Friday, October 13, 2017

An FDA advisory committee made history with its unconditional support for Spark Therapeutics Inc.’s Luxturna, which is on track to become the first gene therapy to be approved in the U.S. to treat an inherited disease. This therapy's early clinical trials were supported in part by the Foundation Fighting Blindness. Read more about the significance of this gene therapy approval in BioWorld here.